Tyrosine kinase inhibitorFDA-approvedSecond-line
Zykadia
Generic name: ceritinib
How it works
Blocks the anaplastic lymphoma kinase (ALK) tyrosine kinase, which is involved in the growth and spread of cancer cells.
Cancer types
Lung Cancer— ALK-positive
Efficacy
In clinical trials, ceritinib improved response rates and progression-free survival in patients with ALK-positive non-small cell lung cancer.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Alectinib Shows Better Results Than Ceritinib in Lung Cancer Study | Lung Cancer | observational | First-line alectinib demonstrated superior intracranial disease control compared with ceritinib (iDCR 97.6% vs. 83.3%, p = 0.026) | Source → |
| New Combination Therapy Shows Promise for Triple-Negative Breast Cancer | Breast Cancer | lab-study | — | Source → |
| Ceritinib Shows Promise in Treating Lung Cancer with Brain Metastases | Lung Cancer | phase-2 | Whole-body ORRs were 35.7%, 30.0%, 50.0%, and 59.1% in different patient groups. | Source → |
| Ceritinib May Help Prevent Bone Loss in Cancer Patients | Lung Cancer | animal-study | — | Source → |
| Combining Cancer Drugs May Improve Treatment for Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Ceritinib's Effect on Other Medications | Lung Cancer | phase-1 | Among the 19 patients with NSCLC, the overall response rate was 42.1% and the disease control rate was 63.2%. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.